Have a personal or library account? Click to login
The Prognostic Value of Troponin Levels Adjusted for Renal Function in Heart Failure – A Systematic Review Cover

The Prognostic Value of Troponin Levels Adjusted for Renal Function in Heart Failure – A Systematic Review

Open Access
|Apr 2025

References

  1. Roger VL. Of Probabilities and Uncertainties: Current Challenges of the Heart Failure Epidemic. JACC Hear Fail. 2018;6(8):686–688. doi:10.1016/J.JCHF.2018.05.003
  2. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–3726. doi:10.1093/eurheartj/ehab368
  3. Han X, Zhang S, Chen Z, et al. Cardiac biomarkers of heart failure in chronic kidney disease. Clin Chim Acta. 2020;510(May):298–310. doi:10.1016/j.cca.2020.07.040
  4. Nagarajan V, Hernandez A V., Tang WHW. Prognostic value of cardiac troponin in chronic stable heart failure: a systematic review. Heart. 2012;98(24):1778–1786. doi:10.1136/HEARTJNL-2012-301779
  5. Latini R, Masson S, Anand IS, et al. Prognostic Value of Very Low Plasma Concentrations of Troponin T in Patients With Stable Chronic Heart Failure. Published online 2007. doi:10.1161/CIRCULATIONAHA.106.655076
  6. Burton JO, Jefferies HJ, Selby NM, McIntyre CW. Hemodialysis-induced cardiac injury: determinants and associated outcomes. Clin J Am Soc Nephrol. 2009;4(5):914–920. doi:10.2215/CJN.03900808
  7. Seliger S. The Cardiorenal Syndrome: Mechanistic Insights and Prognostication with Soluble Biomarkers. Curr Cardiol Rep. 2020;22(10). doi:10.1007/s11886-020-01360-8
  8. Kajimoto H, Kai H, Aoki H, et al. Inhibition of eNOS phosphorylation mediates endothelial dysfunction in renal failure: new effect of asymmetric dimethylarginine. Kidney Int. 2012;81(8):762–768. doi:10.1038/KI.2011.476
  9. Amann K, Breitbach M, Ritz E, Mall G. Myocyte/capillary mismatch in the heart of uremic patients. J Am Soc Nephrol. 1998;9(6):1018–1022. doi:10.1681/ASN.V961018
  10. Sezer S, Karakan S, Ozdemir N. Increased cardiac troponin T levels are related to inflammatory markers and various indices of renal function in chronic renal disease patients. Ren Fail. 2012;34(4):454–459. doi:10.3109/0886022X.2012.656562
  11. London GM. Left ventricular alterations and end-stage renal disease. Nephrol Dial Transplant. 2002;17 Suppl 1(SUPPL. 1):29–36. doi:10.1093/NDT/17.SUPPL_1.29
  12. Bansal N, Anderson AH, Yang W, et al. High-sensitivity troponin T and N-terminal pro-B-type natriuretic peptide (NT-proBNP) and risk of incident heart failure in patients with CKD: The chronic renal insufficiency cohort (CRIC) study. J Am Soc Nephrol. 2015;26(4):946–956. doi:10.1681/ASN.2014010108
  13. Otsuka K, Nakanishi K, Shimada K, et al. Associations of sensitive cardiac troponin-I with left ventricular morphology, function and prognosis in end-stage renal disease patients with preserved ejection fraction. Heart Vessels. 2018;33(11):1334–1342. doi:10.1007/s00380-018-1192-7
  14. Kitagawa M, Sugiyama H, Morinaga H, et al. Serum high-sensitivity cardiac troponin T is a significant biomarker of left-ventricular diastolic dysfunction in subjects with non-diabetic chronic kidney disease. Nephron Extra. 2011;1(1):166–177. doi:10.1159/000333801
  15. Aimo A, Januzzi JL, Vergaro GGV, et al. Prognostic value of high-sensitivity troponin T in chronic heart failure an individual patient data meta-analysis. Circulation. 2018;137(3):286–297. doi:10.1161/CIRCULATIONAHA.117.031560
  16. DeFilippi C, Seliger SL, Kelley W, et al. Interpreting Cardiac Troponin Results from High-Sensitivity Assays in Chronic Kidney Disease without Acute Coronary Syndrome. Clin Chem. 2012;58(9):1342–1351. doi:10.1373/CLINCHEM.2012.185322
  17. Parikh RH, Seliger SL, deFilippi CR. Use and interpretation of high sensitivity cardiac troponins in patients with chronic kidney disease with and without acute myocardial infarction. Clin Biochem. 2015;48(4–5):247–253. doi:10.1016/j.clinbiochem.2015.01.004
  18. Canney M, Tang M, Er L, Barbour SJ, Djurdjev O, Levin A. Glomerular Filtration Rate-Specific Cutoffs Can Refine the Prognostic Value of Circulating Cardiac Biomarkers in Advanced Chronic Kidney Disease. Can J Cardiol. 2019;35(9):1106–1113. doi:10.1016/j.cjca.2019.06.014
  19. Schoenfeld SR, Kasturi S, Costenbader KH. The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: A systematic review. Semin Arthritis Rheum. 2013;43(1):77–95. doi:10.1016/j.semarthrit.2012.12.002
  20. Masson S, Anand I, Favero C, et al. Serial measurement of cardiac troponin T using a highly sensitive assay in patients with chronic heart failure: Data from 2 large randomized clinical trials. Circulation. 2012;125(2):280–288. doi:10.1161/CIRCULATIONAHA.111.044149
  21. Kawahara C, Tsutamoto T, Sakai H, et al. Prognostic value of serial measurements of highly sensitive cardiac troponin i in stable outpatients with nonischemic chronic heart failure. Am Heart J. 2011;162(4):639–645. doi:10.1016/j.ahj.2011.07.007
  22. Zymliński R, Sokolski M, Siwolowski P, et al. Elevated troponin I level assessed by a new high-sensitive assay and the risk of poor outcomes in patients with acute heart failure. Int J Cardiol. 2017;230:646–652. doi:10.1016/j.ijcard.2017.01.012
  23. Demissei BG, Cotter G, Prescott MF, et al. A multimarker multi-time point-based risk stratification strategy in acute heart failure: results from the RELAX-AHF trial. Eur J Heart Fail. 2017;19(8):1001–1010. doi:10.1002/ejhf.749
  24. Ripley TL. Valsartan in chronic heart failure. Ann Pharmacother. 2005;39(3):460–469. doi:10.1345/aph.1E327
  25. GISSI-HF investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9645):1231–1239. doi:10.1016/S0140-6736(08)61240-4
  26. Aulin J, Hijazi Z, Lindbäck J, et al. Biomarkers and heart failure events in patients with atrial fibrillation in the ARISTOTLE trial evaluated by a multi-state model. Am Heart J. 2022;251:13–24. doi:10.1016/j.ahj.2022.03.009
  27. Berge K, Brynildsen J, Roysland R, et al. Prognostic value of cardiac biomarkers and National Early Warning Score 2 in acute dyspnoea. Open Hear. 2022;9(1):1–8. doi:10.1136/openhrt-2021-001938
  28. Aimo A, Januzzi JL, Mueller C, et al. Admission high-sensitivity troponin T and NT-proBNP for outcome prediction in acute heart failure. Int J Cardiol. 2019;293:137–142. doi:10.1016/j.ijcard.2019.06.005
  29. Ledwoch J, Krauth A, Kraxenberger J, et al. Accuracy of high-sensitive troponin depending on renal function for clinical outcome prediction in patients with acute heart failure. Heart Vessels. 2022;37(1):69–76. doi:10.1007/s00380-021-01890-3
  30. Ledwoch J, Kraxenberger J, Krauth A, et al. Prognostic impact of high-sensitive troponin on 30-day mortality in patients with acute heart failure and different classes of left ventricular ejection fraction. Heart Vessels. 2022;37(7):1195–1202. doi:10.1007/s00380-022-02026-x
  31. Berge K, Lyngbakken MN, Myhre PL, et al. High-sensitivity cardiac troponin T and N-terminal pro-B-type natriuretic peptide in acute heart failure: Data from the ACE 2 study. Clin Biochem. 2021;88(October 2020):30–36. doi:10.1016/j.clinbiochem.2020.11.009
  32. Jungbauer CG, Riedlinger J, Block D, et al. Panel of emerging cardiac biomarkers contributes for prognosis rather than diagnosis in chronic heart failure. Biomark Med. 2014;8(6):777–789. doi:10.2217/bmm.14.31
  33. Guisado Espartero ME, Salamanca-Bautista P, Aramburu-Bodas O, et al. Troponin T in acute heart failure: Clinical implications and prognosis in the Spanish National Registry on Heart Failure. Eur J Intern Med. 2014;25(8):739–744. doi:10.1016/j.ejim.2014.08.005
  34. Barlera S, Tavazzi L, Franzosi MG, et al. Predictors of mortality in 6975 patients with chronic heart failure in the gruppo italiano per lo studio della streptochinasi nell'infarto miocardico-heart failure trial proposal for a nomogram. Circ Hear Fail. 2013;6(1):31–39. doi:10.1161/CIRCHEARTFAILURE.112.967828
  35. Masson S, Anand C, Favero S, et al. Serial Measurement of Cardiac Troponin T Using a Highly Sensitive Assay in Patients With Chronic Heart Failure Data From 2 Large Randomized Clinical Trials. Published online 2012. doi:10.1161/CIRCULATIONAHA.111
  36. Lupón J, De Antonio M, Galán A, et al. Combined use of the novel biomarkers high-sensitivity troponin t and st2 for heart failure risk stratification vs conventional assessment. Mayo Clin Proc. 2013;88(3):234–243. doi:10.1016/j.mayocp.2012.09.016
  37. Ather S, Hira RS, Shenoy M, et al. Recurrent low-level Troponin i elevation is a worse prognostic indicator than occasional injury pattern in patients hospitalized with heart failure. Int J Cardiol. 2013;166(2):394–398. doi:10.1016/j.ijcard.2011.10.113
  38. Lok DJ, Klip IT, Lok SI, et al. Incremental prognostic power of novel biomarkers (growth-differentiation factor-15, high-sensitivity C-reactive protein, galectin-3, and high-sensitivity troponin-T) in patients with advanced chronic heart failure. Am J Cardiol. 2013;112(6):831–837. doi:10.1016/j.amjcard.2013.05.013
  39. Egstrup M, Schou M, Tuxen CD, et al. Prediction of outcome by highly sensitive troponin T in outpatients with chronic systolic left ventricular heart failure. Am J Cardiol. 2012;110(4):552–557. doi:10.1016/j.amjcard.2012.04.033
  40. Zhang Y, Guallar E, Blasco-Colmenares E, et al. Clinical and serum-based markers are associated with death within 1 year of de novo implant in primary prevention ICD recipients. Hear Rhythm. 2015;12(2):360–366. doi:10.1016/j.hrthm.2014.10.034
  41. Fabbri A, Marchesini G, Carbone G, et al. Acute heart failure in the emergency department: a follow-up study. Intern Emerg Med. 2016;11(1):115–122. doi:10.1007/s11739-015-1336-z
  42. Lee N, Cho JY, Kim KH, et al. Impact of Cardiac Troponin Elevation on Mortality of Patients with Acute Heart Failure: Insights from the Korea Acute Heart Failure (KorAHF) Registry. J Clin Med. 2022;11(10):1–13. doi:10.3390/jcm11102800
  43. Bayes-Genis A, Zamora E, De Antonio M, et al. Soluble ST2 serum concentration and renal function in heart failure. J Card Fail. 2013;19(11):768–775. doi:10.1016/j.cardfail.2013.09.005
  44. Michael Felker G, Hasselblad V, Wilson Tang WH, et al. Troponin i in acute decompensated heart failure: Insights from the ASCEND-HF study. Eur J Heart Fail. 2012;14(11):1257–1264. doi:10.1093/eurjhf/hfs110
  45. McDowell K, Campbell R, Simpson J, et al. Incremental prognostic value of biomarkers in PARADIGM-HF. Eur J Heart Fail. 2023;25(8):1406–1414. doi:10.1002/ejhf.2887
  46. Tentzeris I, Jarai R, Farhan S, et al. Complementary role of copeptin and high-sensitivity troponin in predicting outcome in patients with stable chronic heart failure. Eur J Heart Fail. 2011;13(7):726–733. doi:10.1093/eurjhf/hfr049
  47. Bjurman C, Jensen J, Petzold M, et al. Assessment of a multimarker strategy for prediction of mortality in older heart failure patients: a cohort study. BMJ Open. 2013;(3). doi:10.1136/bmjopen-2012
  48. Yilmaz Oztekin GM, Genç A. Prognostic Significance of High-Sensitivity Troponin T in Nonischemic Heart Failure with Reduced Ejection Fraction. Turk Kardiyol Dern Ars. 2023;51(2):129–134. doi:10.5543/tkda.2023.26900
  49. Bosselmann H, Egstrup M, Rossing K, et al. Prognostic significance of cardiovascular biomarkers and renal dysfunction in outpatients with systolic heart failure: A long term follow-up study. Int J Cardiol. 2013;170(2):202–207. doi:10.1016/j.ijcard.2013.10.064
  50. HORIUCHI YU, WETTERSTEN N, VELDHUISEN DJ va., et al. Potential Utility of Cardiorenal Biomarkers for Prediction and Prognostication of Worsening Renal Function in Acute Heart Failure. J Card Fail. 2021;27(5):533–541. doi:10.1016/j.cardfail.2020.11.025
  51. O'Connor CM, Fiuzat M, Lombardi C, et al. Impact of serial troponin release on outcomes in patients with acute heart failure: Analysis from the protect pilot study. Circ Hear Fail. 2011;4(6):724–732. doi:10.1161/CIRCHEARTFAILURE.111.961581
  52. Aimo A, Januzzi JL, Vergaro G, et al. High-sensitivity troponin T, NT-proBNP and glomerular filtration rate: A multimarker strategy for risk stratification in chronic heart failure. Int J Cardiol. 2019;277:166–172. doi:10.1016/j.ijcard.2018.10.079
  53. Mueller C, McDonald K, de Boer RA, et al. Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. Eur J Heart Fail. 2019;21(6):715–731. doi:10.1002/ejhf.1494
DOI: https://doi.org/10.2478/rjim-2025-0006 | Journal eISSN: 2501-062X | Journal ISSN: 1220-4749
Language: English
Page range: 107 - 126
Submitted on: Feb 15, 2025
|
Published on: Apr 6, 2025
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2025 Anca Breha, Caterina Delcea, Andreea Cristina Ivanescu, Gheorghe Andrei Dan, published by N.G. Lupu Internal Medicine Foundation
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.